

Corp. Office : 2nd Floor, 'Dorr Oliver' House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai - 400 099.
Tel. : (91-22) 6726 1000 Fax : (91-22) 6726 1068 E-mail : gufic@guficbio.com
CIN L65990MH1984PLCO33519

17/LEGAL/NSE/2014-15/GBSL

13th February, 2015

To,

National Stock Exchange of India Limited,
Exchange Plaza, Bandra - Kurla Complex,
Bandra (E), Mumbai - 400051

Symbol: **GUFICBIO**

Dear Sir/Madam,

Sub: Outcome of the Board of Directors Meeting

With respect to the captioned matter, this is to inform you that meeting of the Board of Directors of the Company was held today, 13th February, 2015, at 4.30 p.m. at the Registered Office of the Company.

Wherein the Board of Directors, among other items, approved the Unaudited Financial Results for the quarter ended on 31st December, 2014. The copy of the said Results is enclosed herewith.

Kindly take the above on record.


Thanking You,

Yours truly,

For Gufic Biosciences Limited



Santosh Sharma
Company Secretary




GUFIC BIOSCIENCES LIMITED						
Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069						
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.12.2014						
	Rs. In Lacs					
Particulars	Quarter Ended 31.12.2014 Unaudited	Quarter Ended 30.09.2014 Unaudited	Quarter Ended 31.12.2013 Unaudited	For the Period Ended 31.12.2014 Unaudited	For the Period Ended 31.12.2013 Unaudited	For the Year Ended 31.03.2014 Audited
INCOME:						
Net Sales / Income from Operations (Net of Excise Duty)	3423.19	4263.81	3130.89	11595.05	8569.25	12291.58
Other Operating Income	10.99	12.58	4.84	25.62	9.06	22.92
Total Income from Operations (Net)	3434.18	4276.39	3135.73	11620.68	8578.31	12314.50
EXPENSES:						
Cost of Materials Consumed	1536.51	2262.43	1299.25	5445.88	3652.46	5194.33
Purchase of Stock-in-Trade	372.16	272.73	433.18	1198.33	903.68	1377.03
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(229.61)	(48.91)	(325.58)	(280.17)	(103.61)	40.87
Employee Benefits Expenses	460.44	457.80	433.09	1285.77	826.25	1194.34
Depreciation and Amortisation Expenses	105.57	103.11	61.38	307.92	182.14	246.77
Other Expenses	950.54	907.55	986.40	2807.99	2414.09	3291.42
Total Expenses	3195.61	3954.71	2887.72	10765.72	7875.01	11344.75
Profit from Operations before Other Income, finance costs and Exceptional Items	238.56	321.69	248.01	854.96	703.30	969.75
Other Income	(1.46)	(11.88)	7.72	15.90	14.95	49.15
Profit from ordinary activities before finance costs and exceptional items	237.10	309.81	255.73	870.86	718.24	1018.90
Finance Costs	101.42	110.94	100.16	318.21	289.54	391.57
Profit from ordinary activities after finance costs but before exceptional items	135.68	198.87	155.58	552.65	428.71	627.32
Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
Profit from Ordinary Activities Before Tax	135.68	198.87	155.58	552.65	428.71	627.32
Current Tax	81.50	103.61	42.50	260.11	109.07	151.00
Deferred Tax	(12.79)	(27.65)	6.45	(16.71)	18.71	7.01
Short/(Excess) Tax Provisions of Earlier Years	(0.69)	4.43	0.00	3.75	0.00	42.90
Net Profit from Ordinary Activities After Tax	67.66	118.47	106.63	305.50	300.93	426.41
Extraordinary Items (Net of Tax Expenses)	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit for the Period	67.66	118.47	106.63	305.50	300.93	426.41
Paid up Equity Share Capital (Face Value of Rs 1/- Each)	773.50	773.50	773.50	773.50	773.50	773.50
Reserves Excluding Revaluation Reserves	1864.57	1796.92	1766.82	1864.57	1766.82	1847.35
E.P.S	0.09	0.15	0.14	0.39	0.39	0.55
Public Shareholding						
-- Number of Shares of Rs 1/- Each	23222355	23222355	23222355	23222355	23222355	23222355
-- Percentage of shareholding	30.02%	30.02%	30.02%	30.02%	30.02%	30.02%
Promoters and Promoter group Shareholding						
a) Pledged / Encumbered						
-- Number of Shares of Rs 1/- Each	0	0	0	0	0	0
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
-- Percentage of Shareholding on total Capital of the company	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
b) Non - Encumbered						
-- Number of Shares of Rs 1/- Each	54127645	54127645	54127645	54127645	54127645	54127645
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
-- Percentage of Shareholding on total Capital of the company	69.98%	69.98%	69.98%	69.98%	69.98%	69.98%

The above Results were reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 13th February, 2015. The Financial Results have been Audited by the Statutory Auditor of the Company

Place: Mumbai
Date: 13.02.2015

For GUFIC BIOSCIENCES LTD.

Jayesh P. Choksi
Managing Director



GUFIC BIOSCIENCES LIMITED

Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069

UNAUDITED SEGMENT WISE RESULTS FOR THE QUARTER ENDED 31.12.2014

Particulars	Quarter Ended 31.12.2014 Unaudited	Quarter Ended 30.09.2014 Unaudited	Quarter Ended 31.12.2013 Unaudited	For the Period Ended 31.12.2014 Unaudited	For the Period Ended 31.12.2013 Unaudited	For the Period Ended 31.03.2014 Audited
SEGMENT REVENUE						
Sales & Service						
Pharma	3253.27	3900.81	2822.90	10709.05	7666.26	11051.26
Consumer	169.91	363.00	307.99	886.01	902.99	1240.32
Total	3423.19	4263.81	3130.89	11595.05	8569.25	12291.58
Unallocabel Income	9.52	0.70	12.56	41.52	24.00	72.07
Total Segment Revenue	3432.71	4264.51	3143.45	11636.58	8593.25	12363.65
SEGMENT RESULTS						
Pharma	634.39	760.68	545.15	2088.26	1484.23	2144.25
Consumer	17.94	38.32	60.59	93.56	175.69	238.83
TOTAL	652.33	798.99	605.74	2181.83	1659.92	2383.08
Less: Unallocated over heads	309.66	386.07	288.63	1003.05	759.54	1117.41
Finance Charges	101.42	110.94	100.16	318.21	289.54	391.57
Depreciation	105.57	103.11	61.38	307.92	182.14	246.77
Tax provision	68.02	80.40	48.95	247.15	127.78	200.91
Net Profit after Tax	67.66	118.47	106.63	305.50	300.93	426.41

Notes forming part of the un-audited financial results for the quarter ended December 31, 2014

- The above interim financial results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors in their meetings held on February 13, 2015. The same has been subjected to limited review by the Statutory Auditors.
- For the preparation of these financial results, the company has followed the same accounting policies and generally accepted practices adopted for the preparation of audited financial statements for the year ended March 31, 2014, except for accounting of depreciation on fixed assets.
- As per the requirement of the Companies Act, 2013 (Act), the company has reassessed the remaining useful life of the fixed assets taking into consideration the useful life prescribed in Schedule II of the Act. This has resulted in an additional charge of depreciation of Rs. 27.54 Lacs for the quarter ended December 31, 2014 and Rs. 50.24 Lacs for the nine Months ended December 31, 2014. Further, the written down value of the assets of Rs. 288.28 Lacs as on April 1, 2014 (net of deferred tax of Rs. 138.45 Lacs) whose residual life is exhausted has been adjusted against the opening balance of Reserves and Surplus.
- Disclosure about investor complaints: Complaints at the beginning of the period Nil, Received during the period Nil; Disposed off during the period: Nil, Unresolved as on December 31, 2014: Nil.
- Corresponding previous period figures have been regrouped / rearranged wherever necessary to make them comparable with current period figures.
- The figures of the last quarter of financial year 2013 – 2014 are the balancing figures between audited figures in respect of the full financial year upto March 31, 2014 and the unaudited published year – to – date figures upto December 31, 2013 which were subject to limited review.

By Order of the Board
Gufic Biosciences LimitedJayesh P. Choksi
Chairman

Mumbai dated February 13, 2015

